What does this research mean for the field?

While digital and intelligent supervision technologies such as AI, blockchain, and electronic prescribing show promise for managing narcotic and psychotropic drugs, prospective clinical evidence remains limited and significant implementation barriers must be addressed. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

August 1, 2026Intelligent PharmacyOpen Access

Current research status and evolutionary trends of intelligent supervision for narcotic and Psychotropic Drugs in Medical Institutions

View Full Paper

Ask AI

Bookmark

Authors

JLJie LiShaoxing University SXShaoyan XuanShaoxing University KZKe ZhangShaoxing University

Discussion

Member takes

Implication

Review reveals variable clinical impacts and technical promise of intelligent drug monitoring systems in healthcare institutions, highlighting persistent implementation and evidentiary gaps.

Key Points

To synthesize current evidence on digital and intelligent supervision technologies for narcotic and psychotropic drugs in medical institutions, evaluating evidence maturity, regulatory frameworks, and implementation barriers.
Synthesized evidence evaluating digital supervision modalities, including Electronic Prescribing for Controlled Substances, prescription drug monitoring programs, artificial intelligence, blockchain, and Internet of Things technologies.
Assessed implementation barriers related to infrastructure, economic costs, workforce training, legacy-system integration, data quality, cybersecurity, privacy, and algorithmic bias.
Electronic Prescribing for Controlled Substances and prescription drug monitoring programs altered prescribing patterns, though magnitude and consistency varied across clinical settings and regulatory environments.
Artificial intelligence models utilizing predictive analytics, natural language processing, and computer vision demonstrated technical efficacy in retrospective validation, but prospective clinical validation remains limited.
Blockchain and Internet of Things applications demonstrated potential for pharmaceutical traceability and automated compliance monitoring, yet evidence specific to controlled substances remains preliminary.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6aaa5121ea9cc040485e4ab2 https://doi.org/10.1016/j.ipha.2026.08.006

View Full Paper

Ask AI

Bookmark

Implication

Review reveals variable clinical impacts and technical promise of intelligent drug monitoring systems in healthcare institutions, highlighting persistent implementation and evidentiary gaps.

Current research status and evolutionary trends of intelligent supervision for narcotic and Psychotropic Drugs in Medical Institutions

Discussion

Member takes

Implication

Key Points

Cite This Study

Current research status and evolutionary trends of intelligent supervision for narcotic and Psychotropic Drugs in Medical Institutions

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider